Literature DB >> 24421674

Does the use of oral nonabsorbable antifungal prophylaxis reduce the incidence of fungal colonization and/or systemic infection in preterm infants?

Russell A Lam1, Kimberly E Dow1.   

Abstract

BACKGROUND: Invasive fungal infection is a significant cause of mortality and morbidity in preterm infants. Oral nonabsorbable agents are used prophylactically, but the literature regarding their effectiveness has not been systematically reviewed.
OBJECTIVE: To determine if oral nonabsorbable antifungal prophylaxis reduces the incidence of fungal colonization and/or systemic infection in preterm infants.
METHODS: The literature was reviewed using the methodology for systematic reviews for the Consensus on Resuscitation Science adapted from the American Heart Association's International Liaison Committee on Resuscitation.
RESULTS: Five studies were reviewed. Three level of evidence 1 studies and two level of evidence 3/4 studies provided evidence that the prophylactic use of oral nonabsorbable antifungal agents can reduce the incidence of fungal colonization and/or systemic fungal infection in preterm infants.
CONCLUSION: Prophylactic oral nonabsorbable antifungal medications are an acceptable approach to reduce colonization and invasive fungal infection in preterm infants in units with high baseline colonization rates.

Entities:  

Keywords:  Antifungal agents; Fungal colonization; Fungal infection; Prophylaxis

Year:  2013        PMID: 24421674      PMCID: PMC3680283     

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  10 in total

1.  Evidence evaluation worksheets: The systematic reviews for the evidence evaluation process for the 2010 International Consensus on Resuscitation Science.

Authors:  Peter Thomas Morley
Journal:  Resuscitation       Date:  2009-05-30       Impact factor: 5.262

Review 2.  Fluconazole prophylaxis in the neonatal intensive care unit.

Authors:  C Mary Healy; Carol J Baker
Journal:  Pediatr Infect Dis J       Date:  2009-01       Impact factor: 2.129

3.  Prevention of invasive Candida infections in preterm infants: the time is now.

Authors:  David A Kaufman
Journal:  Expert Rev Anti Infect Ther       Date:  2008-08       Impact factor: 5.091

Review 4.  Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants.

Authors:  Nicola Austin; Brian A Darlow; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

5.  Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit.

Authors:  Mehmet Adnan Ozturk; Tamer Gunes; Esad Koklu; Neside Cetin; Nedret Koc
Journal:  Mycoses       Date:  2006-11       Impact factor: 4.377

Review 6.  Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

Authors:  D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

7.  Prophylactic oral nystatin and fungal infections in very-low-birthweight infants.

Authors:  M E Sims; Y Yoo; H You; C Salminen; F J Walther
Journal:  Am J Perinatol       Date:  1988-01       Impact factor: 1.862

8.  Oral nystatin prophylaxis and neonatal fungal infections.

Authors:  A Howell; D Isaacs; R Halliday
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2009-03-25       Impact factor: 5.747

9.  Prophylactic oral nystatin for preterm babies under 33 weeks' gestation decreases fungal colonisation and invasive fungaemia.

Authors:  K Ganesan; S Harigopal; T Neal; C W Yoxall
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2008-11-26       Impact factor: 5.747

10.  Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection.

Authors:  S Wainer; P A Cooper; E Funk; R Y Bental; D A Sandler; J Patel
Journal:  Pediatr Infect Dis J       Date:  1992-09       Impact factor: 2.129

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.